IDT and Aldevron, two leading CRISPR gene editing companies, today announced a strategic partnership to expand key CRISPR solutions for cell and gene therapy customers worldwide.
The global distribution agreement enables both companies to work together to deliver key solutions for translational medicine and increase their shared value to the entire CRISPR community. As part of the agreement, in addition to their own research use only (RUO) and current good manufacturing (cGMP) practice CRISPR nucleases, IDT will stock and sell those manufactured by Aldevron. Consequently, this will help advance researchers’ path toward clinical translation, since including cGMP quality documentation is required for regulatory filings.
“IDT and Aldevron are united in accelerating CRISPR research worldwide by working together to deliver key solutions for translational medicine, increasing our shared value to the entire CRISPR community,” said Sandy Ottensmann, VP/GM, Gene Writing and Editing & Core/PCR Business Units at IDT. “Expanding access to best-in-class gene editing reagents and tools to enable customers to rapidly innovate and translate their projects from research breakthroughs to potential life-saving treatments is key to advancing the future of genomic medicine, and we’re proud to work alongside Aldevron to realize this important work.”
Nuclease characteristics
The following Aldevron-manufactured enzymes, engineered to be used in a variety of applications including electroporation, transfection, and microinjection, are now available through IDT:
- SpyFi Cas9 Nuclease—designed for greater editing efficiency and reduced off-target effects. This can deliver higher-fidelity editing with less off-target activity than wild-type SpCas9 nuclease.
- Eureca-V Nuclease—This enzyme supports research and development in the allogeneic cell therapy space.
- SpCas9 Nuclease—a wildtype SpCas9 nuclease for use in development work as well as standard cGMP products for clinical studies.
“Successful clinical translation requires high quality reagents and consistent performance from proof-of-concept through patient dosing. We are thrilled to partner with IDT and bring together their expertise in CRISPR chemistry and oligo production with Aldevron expertise in cGMP CRISPR nuclease and ribonucleoprotein (RNP) manufacturing,” said Tom Foti, Vice President and General Manager of Aldevron’s Protein Business Unit. “By combining manufacturing strengths, from day one, IDT clients now can access Aldevron CRISPR proteins which are designed for clinical translation.”
Orders and further details on the new CRISPR enzymes can be found at: www.idtdna.com/AldevronCRISPRnucleases
